Recent Posts

1. 

   Good luck to all -- hell is coming on the 22nd

   Yes for every quarterly report, BMS will do a layoff and show increased savings!! The LT fucked up big time with 70% revenue coming from 3-4 products and nothing worthwhile in pipeline. No accountability for them. Entire team should be fired

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 6:48 PM

2. 

   Feedback on the New York Regional Manager

   This is true. If they are Purdue then be prepared to be treated like a worthless child. It is all they know

   Scilex Pharmaceuticals

   anonymous

   Apr 25, 2024 at 6:44 PM

3. 

   karuna deal

   Internal candidates given first priority

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 6:36 PM

4. 

   Layoffs

   it’s obvious he didn’t retire as there was no announcement followed by big, fawning thank yous at the sales meeting. These leadership fools never miss an opportunity to circlejerk, and retirement announcements are one of their biggest gets.

   Takeda

   anonymous

   Apr 25, 2024 at 6:32 PM

5. 

   Sell Otezla and Keep Sotyktu?

   Terrible decision. I left Celgene once Amgen puts their KPI claws in, but I am still in derm. Granted, I am now device, but I can say my old customers of 20+ years were disgusted with the attacks on their baby. It's not as if they know it...

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 6:26 PM

6. 

   European Commission approves Astellas’ drug for expanded prostate cancer Treatment

   via On April 24, Astellas Pharma Inc. revealed that XTANDI enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent...

   Pharma/Biotech Companies - In the News

   cafead

   Apr 25, 2024 at 6:22 PM

7. 

   Astrazeneca Tattoo Policy?

   Some dumb ass with barbed wire on their arm or a dolphin on their ass isn’t diversity sweetie.

   AstraZeneca

   anonymous

   Apr 25, 2024 at 6:15 PM

8. + Show More